No image available for this title

LITERATURE

Cardiac Safety and Clinical Efficacy of High Dose Domperidone for Long-Term Treatment of Gastroparesis


Domperidone (D), a dopamine 2 receptor antagonist, is an effective anti-emetic that acts at the chemoreceptor trigger zone and only minimally crosses the blood brain barrier while also exerting prokinetic effects on the stomach and proximal small bowel. D is not approved in the USA. Recommended dosing worldwide is 30 mg/day and due to scattered reports of cardio toxicity
ECG monitoring is recommended. Our goal was to explore the cardiac safety and clinical efficacy of long-term use of D, titrated as high as 120 mg/day, in patients not responding or unable to tolerate other therapies for gastroparesis (GP).


Availability

Vometa-004Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
American Journal of GASTROENTEROLOGY 2019
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous